1-Ethyl-4,4-difluoro-2-methylpyrrolidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: 1-Ethyl-4,4-difluoro-2-methylpyrrolidine
• 英文别名: 1-ethyl-4,4-difluoro-2-methylpyrrolidine
• 化学式: C₇H₁₃F₂N
• 分子量: 149.18
• InChiKey: FPHBNOVOEYNJJI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• [EN] BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS AND PHARMACEUTICAL APPLICATIONS THEREOF<br/>[FR] COMPOSÉS CYCLIQUES PONTÉS EN TANT QU'INHIBITEURS DU VIRUS DE L'HÉPATITE C (HCV) ET LEURS APPLICATIONS PHARMACEUTIQUES
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2014019344A1

  公开（公告）日：2014-02-06

  Provided herein is a compound having Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are pharmaceutical compositions comprising the compounds disclosed herein, which can be used for treating HCV infection or a HCV disorder.

  提供了一种具有公式(I)的化合物，或其立体异构体、几何异构体、互变异构体、N-氧化物、水合物、溶剂化物、代谢物、药用盐或前药，可用于治疗HCV感染或HCV疾病。还提供了包含本公开化合物之一的药物组合物，可用于治疗HCV感染或HCV疾病。
• Amino Compounds for Treatment of Complement Mediated Disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US20150239894A1

  公开（公告）日：2015-08-27

  Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof, wherein R 12 or R 13 on the A group is an amino substituent (R 32 ) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.

  本文提供了公式I或其药学上可接受的盐或组合物所组成的抑制补体因子D的化合物、使用方法和制备过程，其中A组上的R12或R13是氨基取代基（R32）。所述抑制剂靶向因子D并在替代性补体途径的早期和关键点上抑制或调节补体级联反应，并减少因子D调节经典和凝集素补体途径的能力。本文所述的因子D抑制剂能够减少过度激活补体，这与某些自身免疫性、炎症性和神经退行性疾病以及缺血再灌注损伤和癌症有关。
• Aryl, Heteroaryl, and Heterocyclic Compounds for Treatment of Complement Mediated Disorders
  申请人：Achillion Pharmaceuticals, Inc.

  公开号：US20150239895A1

  公开（公告）日：2015-08-27

  Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R 12 or R 13 on the A group is an aryl, heteroaryl or heterocycle (R 32 ) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.

  本文提供了包含式I的补体因子D抑制剂的化合物、使用方法和制备过程，或其药学上可接受的盐或组合物，其中A组上的R12或R13是芳基、杂芳基或杂环（R32）。本文所描述的抑制剂针对因子D并在替代补体途径的早期和关键点上抑制或调节补体级联反应，并减少因子D调节经典和凝集素补体途径的能力。本文所描述的因子D抑制剂能够减少过度激活补体，这与某些自身免疫、炎症和神经退行性疾病、缺血再灌注损伤和癌症有关。
• COMPOUND INHIBITING AND INDUCING DEGRADATION OF EGFR AND ALK
  申请人：Beijing Tide Pharmaceutical Co., Ltd.

  公开号：EP4019021A1

  公开（公告）日：2022-06-29

  A new compound of general formula (X) inhibiting and inducing degradation of an EGFR and ALK, and a pharmaceutical composition containing said compound. The compound and the pharmaceutical composition can be used for treating diseases related to the EGFR and the ALK kinase, such as cancer. The present invention further provides the preparation and use of the compound.

  一种新的通式为（X）的化合物，可抑制和诱导EGFR和ALK的降解，以及包含该化合物的制药组合物。该化合物和制药组合物可用于治疗与EGFR和ALK激酶相关的疾病，如癌症。本发明还提供了该化合物的制备和使用。
• [EN] COMPOUND INHIBITING AND INDUCING DEGRADATION OF EGFR AND ALK<br/>[FR] COMPOSÉ INHIBANT ET INDUISANT LA DÉGRADATION D'EGFR ET D'ALK<br/>[ZH] 抑制并诱导降解EGFR和ALK的化合物
  申请人：BEIJING TIDE PHARMACEUTICAL CO LTD

  公开号：WO2021036922A1

  公开（公告）日：2021-03-04

  一种通式(X)的新的抑制并诱导降解EGFR和ALK的化合物，以及含有所述化合物的药物组合物，它们可用于治疗与EGFR和ALK激酶相关的疾病，例如癌症，及上述化合物的制备和用途。